A Phase 3 interventional study of 13-valent pneumococcal conjugate vaccine (13vPnC) and Blood draw in Invasive Pneumococcal Disease, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 2 sites in Iceland. Open to participants aged 5 Years to 7 Years. Per ClinicalTrials.gov, last updated 2021-11-11.
Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary purpose of this study is to evaluate the immune response to 13-valent pneumococcal conjugate vaccine (13vPnCV) in children who as infants received either a complete series of PnCV versus a combination of PnCV and pneumococcal polysaccharide vaccine (PSV). This study is also intended to evaluate the safety of the 13vPnC.
Follow-up measure for the EMEA supporting a Type II variation for Prevenar (PCV7) label
Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.
First submitted before Wyeth became part of Pfizer.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All subjects will receive a single dose of 13vPnC
Biological: 13-valent pneumococcal conjugate vaccine (13vPnC) · Procedure: Blood draw
0.5 mL intramuscular injection
Collection of 10 mL of blood
Percentage of Participants Achieving a Predefined Serotype-specific Immunoglobulin G (IgG) Antibody Concentration Greater Than or Equal to ( ≥) 0.35 Micrograms Per Milliliter (mcg/mL) Measured 1 Month After Vaccination
Percentage of participants achieving predefined antibody threshold ≥ 0.35 mcg/mL along with the corresponding 95 percent (%) Confidence Interval (CI) for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.
Time frame: Day 28
Percentage of Participants Achieving Opsonophagocytic Assay (OPA) Titers ≥ 1:8 Measured 1 Month After Vaccination
Percentage of participants achieving OPA along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.
Time frame: Day 28
Antibody Response Measured 1 Month After Vaccination (Avidity Assay)
Avidity assay had measurable range of 0.117 to 7.5. Results expressed as avidity index (AI). Geometric mean avidity presented for 3 common pneumococcal serotypes (serotype 6B, 19F, and 23F) and 2 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1 and 5).
Time frame: Day 28
Antibody Response Measured 1 Month After Vaccination (OPA)
Antibody response as measured by OPA, 1 month after vaccination. Geometric mean titers (GMTs) calculated using all participants with available data for the specified blood draw. CIs were back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.
Time frame: Day 28
Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal IgG Antibody 1 Month After Vaccination
Antibody GMC as measured by mcg/mL for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. CIs were back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations. GMCs were calculated using all participants with available data for the specified blood draw.
Time frame: Day 28
Percentage of Participants Reporting Prespecified Local Reactions Within 4 Days of Vaccination
Local reactions were reported by the parent/legal guardian using a diary card. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may have been represented in more than 1 category.
Time frame: Day 1 through Day 4
Percentage of Participants Reporting Prespecified Systemic Reactions Within 4 Days of Vaccination
Pre-specified systemic events (any fever 38 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, and decreased sleep) were reported using a diary card. Participants may have been represented in more than 1 category.
Time frame: Day 1 through Day 4
| Milestone | PCV/23vPS/13vPnC | PCV/PCV/13vPnC |
|---|---|---|
| Started | 50 | 39 |
| Vaccinated | 50 | 39 |
| Completed | 50 | 38 |
| Not completed | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
Percentage of participants achieving predefined antibody threshold ≥ 0.35 mcg/mL along with the corresponding 95 percent (%) Confidence Interval (CI) for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.
| Percentage of participants | PCV/23vPS/13vPnC | PCV/PCV/13vPnC |
|---|---|---|
| Common Serotype 4 | 100.0 (92.9 to 100.0) | 97.3 (85.8 to 99.9) |
| Common Serotype 6B | 100.0 (92.9 to 100.0) | 100.0 (90.5 to 100.0) |
| Common Serotype 9V | 100.0 (92.9 to 100.0) | 100.0 (90.5 to 100.0) |
| Common Serotype 14 | 100.0 (92.7 to 100.0) | 100.0 (90.5 to 100.0) |
| Common Serotype18C | 100.0 (92.9 to 100.0) | 97.3 (85.8 to 99.9) |
| Common Serotype 19F | 100.0 (92.9 to 100.0) | 100.0 (90.5 to 100.0) |
| Common Serotype 23F | 100.0 (92.9 to 100.0) | 100.0 (90.5 to 100.0) |
| Additional Serotype 1 | 100.0 (92.9 to 100.0) | 97.3 (85.8 to 99.9) |
| Additional Serotype 3 | 100.0 (92.9 to 100.0) | 100.0 (90.5 to 100.0) |
| Additional Serotype 5 | 100.0 (92.9 to 100.0) | 100.0 (90.5 to 100.0) |
| Additional Serotype 6A | 100.0 (92.9 to 100.0) | 100.0 (90.5 to 100.0) |
| Additional Serotype 7F | 100.0 (92.9 to 100.0) | 100.0 (90.5 to 100.0) |
| Additional Serotype 19A | 100.0 (92.9 to 100.0) | 100.0 (90.5 to 100.0) |
Percentage of participants achieving OPA along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.
| Percentage of participants | PCV/23vPS/13vPnC | PCV/PCV/13vPnC |
|---|---|---|
| Common Serotype 4 | 98.0 (89.4 to 99.9) | 97.2 (85.5 to 99.9) |
| Common Serotype 6B | 100.0 (92.7 to 100.0) | 100.0 (90.3 to 100.0) |
| Common Serotype 9V | 100.0 (92.7 to 100.0) | 100.0 (90.3 to 100.0) |
| Common Serotype 14 | 100.0 (92.7 to 100.0) | 100.0 (90.3 to 100.0) |
| Common Serotype 18C | 100.0 (92.9 to 100.0) | 100.0 (90.0 to 100.0) |
| Common Serotype 19F | 100.0 (92.7 to 100.0) | 100.0 (90.0 to 100.0) |
| Common Serotype 23F | 98.0 (89.4 to 99.9) | 100.0 (89.7 to 100.0) |
| Additional Serotype 1 | 100.0 (92.9 to 100.0) | 97.3 (85.8 to 99.9) |
| Additional Serotype 3 | 98.0 (89.1 to 99.9) | 100.0 (90.3 to 100.0) |
| Additional Serotype 5 | 98.0 (89.4 to 99.9) | 97.3 (85.8 to 99.9) |
| Additional Serotype 6A | 100.0 (92.9 to 100.0) | 100.0 (90.5 to 100.0) |
| Additional Serotype 7F | 98.0 (89.4 to 99.9) | 100.0 (90.3 to 100.0) |
| Additional Serotype 19A | 100.0 (92.9 to 100.0) | 100.0 (90.5 to 100.0) |
Avidity assay had measurable range of 0.117 to 7.5. Results expressed as avidity index (AI). Geometric mean avidity presented for 3 common pneumococcal serotypes (serotype 6B, 19F, and 23F) and 2 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1 and 5).
| AI | PCV/23vPS/13vPnC | PCV/PCV/13vPnC |
|---|---|---|
| Additional serotype 1 | 1.42 (1.15 to 1.76) | 4.68 (3.62 to 6.04) |
| Additional serotype 5 | 1.85 (1.46 to 2.36) | 5.85 (4.81 to 7.11) |
| Common serotype 6B | 2.43 (1.77 to 3.35) | 5.48 (4.38 to 6.86) |
| Common serotype 19F | 2.17 (1.69 to 2.79) | 2.46 (1.88 to 3.21) |
| Common serotype 23F | 3.02 (2.36 to 3.85) | 6.43 (5.33 to 7.76) |
Antibody response as measured by OPA, 1 month after vaccination. Geometric mean titers (GMTs) calculated using all participants with available data for the specified blood draw. CIs were back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.
| GMT | PCV/23vPS/13vPnC | PCV/PCV/13vPnC |
|---|---|---|
| Common Serotype 4 | 2374 (1656.3 to 3404.0) | 3765 (2339.1 to 6059.8) |
| Common Serotype 6B | 11156 (9073.5 to 13715.2) | 11477 (8418.5 to 15646.8) |
| Common Serotype 9V | 1651 (1067.8 to 2553.3) | 1713 (1087.0 to 2700.0) |
| Common Serotype 14 | 3041 (2311.4 to 4001.1) | 3048 (2318.3 to 4006.9) |
| Common Serotype 18C | 3230 (2616.1 to 3987.1) | 5684 (3122.2 to 10349.6) |
| Common Serotype 19F | 1266 (1013.9 to 1582.0) | 1198 (842.3 to 1703.9) |
| Common Serotype 23F | 1678 (1212.3 to 2322.1) | 2714 (1970.1 to 3739.5) |
| Additional Serotype 1 | 217 (162.6 to 290.5) | 1087 (717.5 to 1646.3) |
| Additional Serotype 3 | 153 (117.2 to 200.2) | 188 (146.6 to 240.8) |
| Additional Serotype 5 | 264 (178.5 to 389.9) | 719 (500.9 to 1032.4) |
| Additional Serotype 6A | 7060 (5352.2 to 9312.6) | 5034 (3336.6 to 7594.4) |
| Additional Serotype 7F | 5835 (4160.0 to 8184.1) | 7887 (6447.9 to 9647.0) |
| Additional Serotype 19A | 1256 (990.9 to 1591.9) | 1556 (1108.8 to 2182.2) |
Antibody GMC as measured by mcg/mL for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. CIs were back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations. GMCs were calculated using all participants with available data for the specified blood draw.
| mcg/mL | PCV/23vPS/13vPnC | PCV/PCV/13vPnC |
|---|---|---|
| Common serotype 4 | 4.18 (3.38 to 5.16) | 11.34 (7.74 to 16.62) |
| Common serotype 6B | 29.51 (21.32 to 40.83) | 41.70 (29.01 to 59.96) |
| Common serotype 9V | 4.31 (3.68 to 5.04) | 7.39 (6.05 to 9.03) |
| Common serotype 14 | 17.47 (12.76 to 23.93) | 22.78 (15.75 to 32.96) |
| Common serotype 18C | 2.76 (2.15 to 3.56) | 4.83 (3.48 to 6.71) |
| Common serotype 19F | 9.78 (7.45 to 12.83) | 11.60 (8.46 to 15.92) |
| Common serotype 23F | 7.89 (6.18 to 10.07) | 12.25 (8.92 to 16.81) |
| Additional serotype 1 | 5.28 (4.22 to 6.61) | 19.43 (13.77 to 27.41) |
| Additional serotype 3 | 3.28 (2.44 to 4.41) | 2.87 (2.19 to 3.76) |
| Additional serotype 5 | 5.75 (4.64 to 7.12) | 15.98 (11.99 to 21.30) |
| Additional serotype 6A | 11.16 (8.80 to 14.16) | 14.07 (10.64 to 18.61) |
| Additional serotype 7F | 7.13 (5.67 to 8.96) | 8.05 (5.94 to 10.91) |
| Additional serotype 19A | 14.62 (11.49 to 18.59) | 17.07 (12.92 to 22.55) |
Local reactions were reported by the parent/legal guardian using a diary card. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may have been represented in more than 1 category.
| Percentage of participants | PCV/23vPS/13vPnC | PCV/PCV/13vPnC |
|---|---|---|
| Tenderness: Any | 88.0 | 76.9 |
| Tenderness: Significant | 12.0 | 20.5 |
| Redness: Any | 50.0 | 66.7 |
| Redness: Mild | 10.0 | 15.8 |
| Redness: Moderate | 40.0 | 52.6 |
| Redness: Severe | 10.0 | 21.1 |
| Swelling: Any | 44.0 | 59.0 |
| Swelling: Mild | 16.3 | 26.3 |
| Swelling: Moderate | 28.6 | 44.7 |
| Swelling: Severe | 2.0 | 7.9 |
Pre-specified systemic events (any fever 38 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, and decreased sleep) were reported using a diary card. Participants may have been represented in more than 1 category.
| Percentage of participants | PCV/23vPS/13vPnC | PCV/PCV/13vPnC |
|---|---|---|
| Fever ≥ 38 degrees C but ≤ 39 degrees C | 2.0 | 2.8 |
| Decreased appetite | 12.2 | 10.3 |
| Irritability | 18.4 | 11.4 |
| Increased sleep | 4.0 | 12.8 |
| Decreased sleep | — | 5.1 |
| Rash | 6.0 | 2.6 |
Collected over Baseline through 1 Month after last study vaccination (28 Days). Local reactions and systemic events assessed within 4 days of dose (Day 1 through Day 4). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PCV/23vPS/13vPnC | — | 0/50 (0%) | 44/50 (88%) |
| PCV/PCV/13vPnC | — | 0/39 (0%) | 30/39 (76.9%) |
| Event | PCV/23vPS/13vPnC | PCV/PCV/13vPnC |
|---|---|---|
| Tenderness (Any)Skin and subcutaneous tissue disorders | 44/50 | 30/39 |
| Redness (Any)Skin and subcutaneous tissue disorders | 25/50 | 26/39 |
| Swelling (Any)Skin and subcutaneous tissue disorders | 22/50 | 23/39 |
| Redness (Moderate)Skin and subcutaneous tissue disorders | 20/50 | 20/38 |
| Swelling (Moderate)Skin and subcutaneous tissue disorders | 14/49 | 17/38 |
| Swelling (Mild)Skin and subcutaneous tissue disorders | 8/49 | 10/38 |
| Redness (Severe)Skin and subcutaneous tissue disorders | 5/50 | 8/38 |
| Tenderness (Significant)Skin and subcutaneous tissue disorders | 6/50 | 8/39 |
| IrritabilityGeneral disorders | 9/49 | 4/35 |
| Redness (Mild)Skin and subcutaneous tissue disorders | 5/50 | 6/38 |
| Age, Continuous(years) | PCV/23vPS/13vPnC | PCV/PCV/13vPnC | Total |
|---|---|---|---|
| Mean | 7.6 ± 0.2 | 7.6 ± 0.2 | 7.6 ± 0.2 |
| Sex: Female, Male(Participants) | PCV/23vPS/13vPnC | PCV/PCV/13vPnC | Total |
|---|---|---|---|
| Female | 25 | 20 | 45 |
| Male | 25 | 19 | 44 |
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from May 2009 to primary completion in Dec 2009, 7 months.
Results were first posted in Jan 2011, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 13-valent pneumococcal vaccine
Wyeth is now a wholly owned subsidiary of Pfizer →